- Olaparib Plus Durvalumab and Bevacizumab Provides Durable Survival in Non-Germline, BRCA+ Relapsed Ovarian Cancer.
- Seymour C.
- OncLive. 2022 Dec 4.
- Research news
- Free Full Text
•• Identifier: NCT02734004: A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA). (ClinicalTrials.gov . Accessed 2022 Dec 4.)
- Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
- Liu Y, Zhu J, Wei X, Yang D, Li S, Qian X, Li L.
- J Ovarian Res. 2022 Dec 3;15(1):127. doi: 10.1186/s13048-022-01069-y.
- PMID: 36463302
- PubMed abstract
- Case report
- Free Full Text
- NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer.
- Jung K, Lee S, Na HY, Kim JW, Lee JC, Hwang JH, Kim JW, Kim J.
- Sci Rep. 2022 Dec 3;12(1):20937. doi: 10.1038/s41598-022-24732-2.
- PMID: 36463295
- PubMed abstract
- Immediate Breast Reconstruction Using the Autologous Dermal Flap.
- Kaviani A, Ashraf-Ganjouei A, Vasigh M, Zand S, Patocskai E.
- J Surg Res. 2022 Nov 30;283:713-718. doi: 10.1016/j.jss.2022.11.002. Epub ahead of print.
- PMID: 36462381
- PubMed abstract
- Source abstract